At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Citalopramdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
In Brief
A Phase 4 clinical trial evaluating Citalopram for Major Depressive Disorder. Completed, enrolled 65 participants across 1 site.
Detailed Summary
Studies of the neural mechanisms underlying placebo effects in antidepressant clinical trials largely have been limited to demonstrating objective differences in brain activity between responders and non-responders to placebo. This 8 week Placebo-controlled and Open groups study employs a novel antidepressant trial design with integrated functional magnetic resonance imaging (fMRI) to manipulate patient expectancy and examine its neural mediators.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedAug 2013
Primary CompletionJun 2016
TodayJul 2026
First PostedAug 8, 2013
Enrollment StartJan 1, 2010
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 12.9 years ago
Interventions
Citalopramdrug